ClinVar Miner

Submissions for variant NM_001458.5(FLNC):c.4952G>A (p.Gly1651Asp)

gnomAD frequency: 0.00001  dbSNP: rs762493974
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000726915 SCV000573342 uncertain significance not provided 2017-02-16 criteria provided, single submitter clinical testing The G1651D variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. The G1651D variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). This variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved in mammals, and in silico analysis predicts this variant is probably damaging to the protein structure/function. However, missense variants in nearby residues have not been reported in the Human Gene Mutation Database in association with FLNC-related disorders (Stenson et al., 2014).
Eurofins Ntd Llc (ga) RCV000726915 SCV000704142 uncertain significance not provided 2016-11-30 criteria provided, single submitter clinical testing
Invitae RCV001215135 SCV001386863 uncertain significance Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant 2023-08-31 criteria provided, single submitter clinical testing This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 1651 of the FLNC protein (p.Gly1651Asp). This variant is present in population databases (rs762493974, gnomAD 0.04%). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 423624). This variant has not been reported in the literature in individuals affected with FLNC-related conditions.
Ambry Genetics RCV002341149 SCV002642868 uncertain significance Cardiovascular phenotype 2019-08-06 criteria provided, single submitter clinical testing The p.G1651D variant (also known as c.4952G>A) is located in coding exon 30 of the FLNC gene. The glycine at codon 1651 is replaced by aspartic acid, an amino acid with similar properties. This change occurs in the first base pair of coding exon 30. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Revvity Omics, Revvity RCV000726915 SCV003833111 uncertain significance not provided 2019-11-16 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.